Terms: = Lymphoma AND PIM1, PIM, 5292, ENSG00000137193, P11309 AND Treatment
67 results:
1. Mutation landscape in Chinese nodal diffuse large B-cell lymphoma by targeted next generation sequencing and their relationship with clinicopathological characteristics.
Cao B; Sun C; Bi R; Liu Z; Jia Y; Cui W; Sun M; Yu B; Li X; Zhou X
BMC Med Genomics; 2024 Apr; 17(1):84. PubMed ID: 38609996
[TBL] [Abstract] [Full Text] [Related]
2. Dynamic monitoring of circulating tumor DNA reveals outcomes and genomic alterations in patients with relapsed or refractory large B-cell lymphoma undergoing CAR T-cell therapy.
Zou H; Liu W; Wang X; Wang Y; Wang C; Qiu C; Liu H; Shan D; Xie T; Huang W; Sui W; Yi S; An G; Xu Y; Ma T; Wang J; Qiu L; Zou D
J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38443094
[TBL] [Abstract] [Full Text] [Related]
3. Comprehensive Insights that Targeting pim for Cancer Therapy: Prospects and Obstacles.
Chen L; Mao W; Ren C; Li J; Zhang J
J Med Chem; 2024 Jan; 67(1):38-64. PubMed ID: 38164076
[TBL] [Abstract] [Full Text] [Related]
4. KZ02 enhances the radiosensitivity of BRAF-mutated CRC in vitro and in vivo.
Guo Y; Li X; Yuan R; Ren J; Huang Y; Yu Y; Tian H
Eur J Pharmacol; 2023 Nov; 959():176060. PubMed ID: 37775019
[TBL] [Abstract] [Full Text] [Related]
5. Analysis of genomic alterations in primary central nervous system lymphoma.
He X; Fan X; Shan Y; Ji X; Su L; Wang Y
Medicine (Baltimore); 2023 Sep; 102(35):e34931. PubMed ID: 37657032
[TBL] [Abstract] [Full Text] [Related]
6. Circulating Tumor DNA Reflects Histologic and Clinical Characteristics of Various lymphoma Subtypes.
Kim JJ; Kim HM; Kim H; Kim SJ; Lee ST; Choi JR; Shin S; Hwang DY
Cancer Res Treat; 2024 Jan; 56(1):314-323. PubMed ID: 37475138
[TBL] [Abstract] [Full Text] [Related]
7. Elraglusib (formerly 9-ING-41) possesses potent anti-lymphoma properties which cannot be attributed to GSK3 inhibition.
Coats JT; Tauro S; Sutherland C
Cell Commun Signal; 2023 Jun; 21(1):131. PubMed ID: 37316860
[TBL] [Abstract] [Full Text] [Related]
8. Phase 1/2 Study of the Pan-pim Kinase Inhibitor INCB053914 Alone or in Combination With Standard-of-Care Agents in Patients With Advanced Hematologic Malignancies.
Patel MR; Donnellan W; Byrne M; Asch AS; Zeidan AM; Baer MR; Fathi AT; Kuykendall AT; Zheng F; Walker C; Cheng L; Marando C; Savona MR
Clin Lymphoma Myeloma Leuk; 2023 Sep; 23(9):674-686. PubMed ID: 37290996
[TBL] [Abstract] [Full Text] [Related]
9. Relationship between BCL2 mutations and follicular lymphoma outcome in the chemoimmunotherapy era.
Correia C; Maurer MJ; McDonough SJ; Schneider PA; Ross PE; Novak AJ; Feldman AL; Cerhan JR; Slager SL; Witzig TE; Eckloff BW; Li H; Nowakowski GS; Kaufmann SH
Blood Cancer J; 2023 May; 13(1):81. PubMed ID: 37193683
[TBL] [Abstract] [Full Text] [Related]
10. MYD88
Qin Y; Qiu T; Xie Z; Chen X; Liu P; Yang J; He X; Gui L; Zhou S; Jiang H; Zhang C; Yang S; Tang L; Shi Y
J Cancer Res Clin Oncol; 2023 Sep; 149(11):8483-8494. PubMed ID: 37093346
[TBL] [Abstract] [Full Text] [Related]
11. Genomic landscape of follicular lymphoma across a wide spectrum of clinical behaviors.
Mozas P; López C; Grau M; Nadeu F; Clot G; Valle S; Kulis M; Navarro A; Ramis-Zaldivar JE; González-Farré B; Rivas-Delgado A; Rivero A; Frigola G; Balagué O; Giné E; Delgado J; Villamor N; Matutes E; Magnano L; García-Sanz R; Huet S; Russell RB; Campo E; López-Guillermo A; Beà S
Hematol Oncol; 2023 Oct; 41(4):631-643. PubMed ID: 36994552
[TBL] [Abstract] [Full Text] [Related]
12. Trends in Survival Rates of Non-Small Cell Lung Cancer With Use of Molecular Testing and Targeted Therapy in Korea, 2010-2020.
Chi SA; Yu H; Choi YL; Park S; Sun JM; Lee SH; Ahn JS; Ahn MJ; Choi DH; Kim K; Jung HA; Park K
JAMA Netw Open; 2023 Mar; 6(3):e232002. PubMed ID: 36929402
[TBL] [Abstract] [Full Text] [Related]
13. The outcome of ibrutinib-based regimens in relapsed/refractory central nervous system lymphoma and the potential impact of genomic variants.
Wang S; Zhu Y; Qian X; Ding T; Yuan Y; Li Y; Wu H; Chen T
Adv Clin Exp Med; 2023 Aug; 32(8):855-863. PubMed ID: 36881367
[TBL] [Abstract] [Full Text] [Related]
14. Role and mechanism of pim family in the immune microenvironment of diffuse large B cell lymphoma.
Wang C; Chen Q; Luo H; Chen R
World J Surg Oncol; 2023 Mar; 21(1):76. PubMed ID: 36871027
[TBL] [Abstract] [Full Text] [Related]
15. Testicular Relapse of Primary Diffuse Large B-cell lymphoma of the Central Nervous System - a Rare Occurrence.
Ollila TA; Kishkovich TP; Olszewski AJ; Patel NR; Jackson C; Roussel B; Niroula R; Treaba DO
R I Med J (2013); 2023 Mar; 106(2):8-12. PubMed ID: 36848533
[TBL] [Abstract] [Full Text] [Related]
16. Mutation profiling of circulating tumor DNA identifies distinct mutation patterns in non-Hodgkin lymphoma.
Fu H; Shen J; Zhou H; Zhang F; Li H; Ma Z; Huang W; Chen L; Chen Y; Liu T
Eur J Haematol; 2022 Apr; 108(4):298-309. PubMed ID: 34997652
[TBL] [Abstract] [Full Text] [Related]
17. Inhibition of pim Kinases in DLBCL Targets MYC Transcriptional Program and Augments the Efficacy of Anti-CD20 Antibodies.
Szydłowski M; Garbicz F; Jabłońska E; Górniak P; Komar D; Pyrzyńska B; Bojarczuk K; Prochorec-Sobieszek M; Szumera-Ciećkiewicz A; Rymkiewicz G; Cybulska M; Statkiewicz M; Gajewska M; Mikula M; Gołas A; Domagała J; Winiarska M; Graczyk-Jarzynka A; Białopiotrowicz E; Polak A; Barankiewicz J; Puła B; Pawlak M; Nowis D; Golab J; Tomirotti AM; Brzózka K; Pacheco-Blanco M; Kupcova K; Green MR; Havranek O; Chapuy B; Juszczyński P
Cancer Res; 2021 Dec; 81(23):6029-6043. PubMed ID: 34625423
[TBL] [Abstract] [Full Text] [Related]
18. c-MYC and p53 expression highlight starry-sky pattern as a favourable prognostic feature in R-CHOP-treated diffuse large B-cell lymphoma.
Bouroumeau A; Bussot L; Bonnefoix T; Fournier C; Chapusot C; Casasnovas O; Martin L; McLeer A; Col E; David-Boudet L; Lefebvre C; Algrin C; Raskovalova T; Jacob MC; Vettier C; Chevalier S; Callanan MB; Gressin R; Emadali A; Sartelet H
J Pathol Clin Res; 2021 Nov; 7(6):604-615. PubMed ID: 34374220
[TBL] [Abstract] [Full Text] [Related]
19. Plasma Circulating Tumor DNA in Patients with Primary Central Nervous System lymphoma.
Yoon SE; Kim YJ; Shim JH; Park D; Cho J; Ko YH; Park WY; Mun YC; Lee KE; Cho D; Kim WS; Kim SJ
Cancer Res Treat; 2022 Apr; 54(2):597-612. PubMed ID: 34325497
[TBL] [Abstract] [Full Text] [Related]
20. Proposal and validation of a method to classify genetic subtypes of diffuse large B cell lymphoma.
Pedrosa L; Fernández-Miranda I; Pérez-Callejo D; Quero C; Rodríguez M; Martín-Acosta P; Gómez S; González-Rincón J; Santos A; Tarin C; García JF; García-Arroyo FR; Rueda A; Camacho FI; García-Cosío M; Heredero A; Llanos M; Mollejo M; Piris-Villaespesa M; Gómez-Codina J; Yanguas-Casás N; Sánchez A; Piris MA; Provencio M; Sánchez-Beato M
Sci Rep; 2021 Jan; 11(1):1886. PubMed ID: 33479306
[TBL] [Abstract] [Full Text] [Related]
[Next]
